Related Experiment Video
Updated: Aug 17, 2026

Multimodality Diagnosis of Mesenteric Ischemia
Published on: July 21, 2023
Non-occlusive mesenteric ischemia in chronically dialyzed patients: a disease with multiple risk factors
Yaacov Ori1, Avry Chagnac, Ariel Schwartz
1Department of Nephrology, Rabin Medical Center (Hasharon), Petah-Tikva, Israel.
Background:
Non-occlusive mesenteric ischemia (NOMI) can be a fatal complication in dialysis patients. Intradialytic hypotension is usually the precipitating factor. The occurrence of 16 cases in 5 years (1998-2002), compared with only 4 in previous years, led us to investigate other risk factors contributing to NOMI. A control group of stable hemodialysis patients was used for comparison.
Results:
20 patients were studied: 17 diagnosed surgically, and 3 clinically. The mean age was 70.8 +/- 1.8 years, and the male:female ratio 7:13. Nineteen patients were on hemodialysis. Clinically overt atherosclerosis was present in 17 patients. Preceding dialysis-associated hypotension was identified in all patients studied and access thrombosis in 6 patients. In all patients, abdominal pain was the presenting symptom. Initial abdominal examination was unimpressive in 16 patients. The hemoconcentration, leukocytosis and metabolic acidosis were the most prominent laboratory findings. 5/11 abdominal sonograms showed intestinal pathology. 2/3 angiographies were diagnostic. Three patients responded to early fluid challenge and did not require surgery. Pathology was related to the area of the superior mesenteric artery in all 15 patients operated. Twelve (60%) patients died from the event. The 1-year mortality rate was 17/20 patients (85%). Possible contributing factors, other than dialysis-associated hypotension, included: high-dose recombinant human erythropoietin (rhEPO) therapy (179 +/- 35 vs. 116 +/- 10 U/kg/week in the control group, p < 0.05); metastatic calcifications (abdominal aorta 14/14, aortic valve 11/18; medial calcification of mesenteric arteries in 2/11 pathology specimens); digoxin, and hypoalbuminemia.
Conclusions:
The increased incidence of NOMI in dialysis patients may be related to overly aggressive rhEPO therapy and the unsuspected presence of mesenteric arterial medial calcifications. Identification of patients at risk, prevention of intradialytic hypotension and a controlled increase in dry weight may help to reduce the incidence of NOMI in chronically dialyzed patients.
Insights
Non-occlusive mesenteric ischemia (NOMI) in dialysis patients is often fatal. Aggressive recombinant human erythropoietin (rhEPO) therapy and mesenteric artery calcifications may increase NOMI risk, alongside intradialytic hypotension.
Area of Science:
- Nephrology
- Gastroenterology
- Vascular Surgery
Background:
- Non-occlusive mesenteric ischemia (NOMI) is a serious complication in dialysis patients, often triggered by intradialytic hypotension.
- An observed increase in NOMI cases prompted an investigation into additional risk factors beyond hypotension.
Purpose of the Study:
- To identify risk factors contributing to the increased incidence of NOMI in dialysis patients.
- To compare risk factors in NOMI patients with a control group of stable hemodialysis patients.
Main Methods:
- Retrospective study of 20 NOMI patients (19 on hemodialysis) and a control group of stable hemodialysis patients.
- Analysis of clinical data, laboratory findings, imaging (sonography, angiography), and pathology specimens.
- Comparison of high-dose recombinant human erythropoietin (rhEPO) therapy, metastatic calcifications, digoxin use, and hypoalbuminemia between groups.
Main Results:
- NOMI patients were older (mean age 70.8 years) with a high prevalence of atherosclerosis (17/20).
- Dialysis-associated hypotension preceded NOMI in all cases; high-dose rhEPO therapy (p < 0.05) and mesenteric arterial calcifications were significantly associated with NOMI.
- Mortality was high, with 60% dying from the event and an 85% 1-year mortality rate.
Conclusions:
- Increased NOMI incidence in dialysis patients may be linked to aggressive rhEPO therapy and unrecognized mesenteric arterial medial calcifications.
- Preventative strategies include identifying at-risk patients, preventing intradialytic hypotension, and carefully managing dry weight.
More Related Videos
07:05Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy
Published on: September 27, 2024
04:57Controlled Reversible Visceral Arterial Ischemia, Venous Congestion and Combined Malperfusion via Midline Laparotomy in Rats
Published on: July 5, 2024
Related Concept Videos
Peripheral Artery Disease I: Introduction
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Ischemic Stroke l: Introduction